1,894
+0.64%
Close of 6 Nov 2026, in JPY
About Santen Pharmaceutical Co
Its shares trade on Tokyo Stock Exchange under the ticker 4536.T. It has been listed since 4 November 1963. In the fiscal year to 31 March 2026, it reported revenue of ¥291.62bn and net income of ¥37.37bn. At that date it held total assets of ¥423.03bn and shareholders' equity of ¥296.99bn.
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. The company is headquartered in Osaka, Osaka-Fu. The firm has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The firm engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The firm operates in Japan, Europe, Asia, North America markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 4 Nov 1963
- Employees
- 4,108
- Website
- santen.co.jp ↗
Leadership
Pay as last reported
- Mr. Akira KurokawaChairman of the Board, since 2006¥217.0m
- Mr. Takeshi ItoPresident, Chief Executive Officer, Representative Director, since 2012¥178.0m
- Mr. Kazuo KoshijiChief Financial Officer, Chief Risk Officer, Executive Officer
- Mr. Rie NakajimaChief Operating Officer, Executive Officer, Director, since 2023
- Ms. Mika MasunariChief Compliance Officer, Executive Officer, General Counsel
- Mr. Shinichi TeramachiExecutive Officer, Director of Japan Business Ophthalmology Business, Senior Director in Main Sales Supervision Unit
- Mr. Ippei KuriharaExecutive Officer, Director, since 2021
- Mr. Fumiyasu AkoExecutive Officer
- Mr. Ken ArakiExecutive Officer, Global Head of Business Development
- Mr. Frank BinderExecutive Officer, Chief Director of Supply Chain
- Mr. Mark DawsonExecutive Officer, Chief Product Supply Officer
- Mr. Reza HaqueExecutive Officer, Manager of Ophthalmology Innovation Center
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 99
- Governance
- 66
- Direct emissions (scope 1)
- 17,021 t
- Energy emissions (scope 2)
- 22,591 t
- Value chain emissions (scope 3)
- 196,579 t
- Women in the workforce
- 44.1%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Santen Pharmaceutical Co Ltd boasts several strengths that contribute to its success and positioning in the market. Firstly, the company has a strong portfolio of innovative and high-quality pharmaceutical products across multiple therapeutic areas. This diverse range of offerings allows Santen to cater to a wide customer base and meet various medical needs.
- Additionally, Santen has established itself as a leader in the ophthalmic industry. The company has a deep understanding of ocular health and has developed specialized expertise in this field. With this focus, Santen can provide targeted solutions for eye-related conditions, enabling it to gain a competitive edge.
- Santen's commitment to research and development further strengthens its position. The company invests significant resources into innovation, continuously working to improve existing products and develop new treatments. This dedication to research enhances Santen's ability to stay ahead in the ever-evolving pharmaceutical industry.
Weaknesses
- Despite its strengths, Santen Pharmaceutical Co Ltd faces certain weaknesses that can hinder its growth and performance. One notable weakness is its limited geographical presence. The company primarily operates within the Asian market, which limits its access to other potentially lucrative regions. Expanding into new markets could provide Santen with opportunities for further growth and revenue generation.
- Furthermore, Santen's heavy reliance on a specific therapeutic area, namely ophthalmology, exposes it to potential risks. Any adverse developments in this field could significantly impact the company's financial performance. Diversifying its product offerings across various therapeutic areas could mitigate this vulnerability.
Opportunities
- Santen Pharmaceutical Co Ltd operates in an industry with numerous opportunities for expansion and development. The growing global population, particularly in aging societies, presents a significant opportunity for the company. Age-related eye diseases, such as cataracts and glaucoma, are becoming more prevalent, creating a higher demand for ophthalmic treatments and medications. Santen can capitalize on this trend by developing innovative solutions tailored to address the specific needs of these patients.
- Additionally, expanding into new markets, especially in regions with emerging economies, offers considerable growth potential. By establishing a presence in these markets, Santen can tap into a larger customer base and leverage increasing healthcare expenditure in these regions.
Threats
- Santen Pharmaceutical Co Ltd faces certain threats that could impact its operations and market position. One significant threat is the intense competition within the pharmaceutical industry. Numerous companies are vying for market share, and Santen must continuously innovate and differentiate itself to retain its competitive advantage.
- Furthermore, regulatory challenges and the need for stringent compliance pose potential threats. Adhering to various regulations and maintaining high safety standards across different markets can be complex and costly. Failure to comply could result in legal consequences and damage to the company's reputation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.